<DOC>
	<DOCNO>NCT00002842</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness surgery follow floxuridine plus systemic fluorouracil leucovorin treat patient liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Liver Resection Floxuridine Plus Fluorouracil Leucovorin Treating Patients With Liver Metastases From Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy hepatic resection follow portal vein infusion floxuridine plus systemic fluorouracil/leucovorin calcium patient metastatic colorectal cancer . - Study toxic effect adjuvant chemotherapy follow hepatic resection . - Evaluate mRNA expression enzyme may important cytotoxicity fluoropyrimidines tumor cell , include thymidylate synthase , ribonucleotide reductase , folylglutamyl synthetase , polymerase chain reaction immunohistochemistry . OUTLINE : Following resection liver extrahepatic colorectal cancer , patient receive floxuridine via portal vein infusion day 1-14 . Systemic chemotherapy consist leucovorin calcium day 8-14 fluorouracil day 9-13 . Courses repeat every 4 week total 12 week . If biopsy-proven metastatic disease develop , treatment may stop investigator 's discretion . Continuation regional therapy consider extrahepatic failure . No concurrent radiotherapy permit . Patients follow every 3 month 3 year , every 6 month survival . PROJECTED ACCRUAL : It expect 50 patient enter approximately 5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal carcinoma radiologically confirm colorectal carcinoma synchronous metastasis Intrahepatic metastasis require No 15 metastasis involve 60 % function liver No extrahepatic disease unless : Resectable anastomotic locally recurrent tumor Resectable mesenteric lymph node involvement patient undergoing initial resection primary colorectal carcinoma Disease extension liver metastasis amenable en bloc resection ( e.g. , diaphragm wall , kidney , abdominal wall ) No biopsyproven chronic active hepatitis PATIENT CHARACTERISTICS : Age : Physiologic 18 70 Performance status : Karnofsky 60 % 100 % Hematopoietic : AGC least 1,500 Platelets least 100,000 Hepatic : Bilirubin great 2.0 mg/dL ( unless reversibly obstruct metastasis ) Renal : Creatinine great 2.0 mg/dL Other : No second malignancy within 5 year except adequately treat : Nonmelanomatous skin cancer In situ bladder cancer In situ cervical cancer No pregnant woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior mitomycin nitrosoureas allow Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy liver At least 3 week since radiotherapy recover Prior pelvic radiotherapy allow No plan concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>